Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Meiji HD to Create Meiji Seika Pharma in April 2011
October 4, 2010
- 1,021 HIV-Infected Cases Reported in 2009: Korosho AIDS Survey
October 4, 2010
- Cancer Pain Relieving Agent Tramal: Nippon Shinyaku
October 4, 2010
- BI's SGLT-2 Inhibitor Reduces Both HbA1c and Weight
October 4, 2010
- Kissei Licenses Drug for yperphosphatemia from Vifor Pharma
October 4, 2010
- 19 Products Added to NHI Price List
October 4, 2010
- Dapagliflozin Non-Inferior to SU
October 4, 2010
- Takeda to Construct New Formulation Plant in Hikari
October 4, 2010
- Banyu Warned about Payment to Doctors Attending Januvia Seminars
October 4, 2010
- Canagliflozin Significantly Reduces HbA1c, Weight in PIIb
October 4, 2010
- Takeda Launches Dexilant in Canada
October 4, 2010
- EMA Recommends Suspension, US FDA Restricts Access to Avandia
October 4, 2010
- Diabetes Increasing in Asia: EASD President Prof. Smith
October 4, 2010
- MTPC Transfers 3 Long-Listed Products to Its Subsidiary
October 4, 2010
- Ono Applies for the Antiemetic Fosaprepitant
October 4, 2010
- EASD Welcomes GL Proposed by EMA
October 4, 2010
- BMS to Acquire ZymoGenetics through Tender Offer
October 4, 2010
- Dabigatran Receives Recommendation by FDA Committee: BI
October 4, 2010
- Otsuka to Codevelop OPA-6566 for Glaucoma with Acucela
October 4, 2010
- Daiichi Sankyo Completes Tender Offer for Zenotech Lab
October 4, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…